Protagonist Therapeutics, Inc. (PTGX)

Protagonist Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	113.71	97.25	186.73	125.74	123.67	117.36
Short-Term Investments	462.4	321.66	154.89	111.61	203.24	188.45
Cash & Short-Term Investments	576.12	418.91	341.62	237.36	326.9	305.81
Cash Growth	22.91%	22.63%	43.93%	-27.39%	6.90%	129.90%
Accounts Receivable	0.58	165	10	0.01	1.57	2.43
Other Receivables	4.74	3.49	0.33	0.04	3.77	1.4
Receivables	5.33	168.49	10.33	0.05	5.33	3.82
Prepaid Expenses	4.98	4.24	3.63	5.67	8.5	5.97
Restricted Cash	-	-	-	-	-	0.01
Total Current Assets	586.42	591.64	355.58	243.08	340.74	315.61
Property, Plant & Equipment	12.27	12.61	2.15	4.63	6.73	6.41
Long-Term Investments	102.7	140.25	-	-	-	2
Other Long-Term Assets	0.29	0.23	0.23	0.23	0.23	0.45
Total Assets	701.69	744.73	357.95	247.93	347.7	324.47
Accounts Payable	5.65	1.62	0.77	3.64	1.6	3.08
Accrued Expenses	22.68	23.62	19.26	24.54	37.31	18.42
Current Portion of Leases	2.23	0.51	1.14	2.52	2.2	1.46
Current Income Taxes Payable	-	2.69	-	-	-	-
Current Unearned Revenue	14.2	18.89	-	-	1.6	14.48
Other Current Liabilities	0.19	0.07	0.1	0.48	1.31	2.81
Total Current Liabilities	44.94	47.4	21.27	31.18	44.02	40.24
Long-Term Leases	8.52	10.36	-	1.14	3.66	4.5
Long-Term Unearned Revenue	2.79	11.68	-	-	-	-
Other Long-Term Liabilities	-	-	-	-	-	0.12
Total Liabilities	56.25	69.43	21.27	32.32	47.67	44.86
Common Stock	0	0	0	-	-	-
Additional Paid-In Capital	1,071	1,016	952.49	752.72	709.68	563.39
Retained Earnings	-426.29	-340.52	-615.71	-536.76	-409.36	-283.81
Comprehensive Income & Other	0.53	-0.08	-0.11	-0.36	-0.3	0.03
Total Common Equity	645.44	675.3	336.68	215.61	300.02	279.61
Shareholders' Equity	645.44	675.3	336.68	215.61	300.02	279.61
Total Liabilities & Equity	701.69	744.73	357.95	247.93	347.7	324.47
Total Debt	10.75	10.87	1.14	3.66	5.86	5.96
Net Cash (Debt)	668.07	548.3	340.48	233.7	321.04	301.85
Net Cash Growth	16.72%	61.04%	45.69%	-27.21%	6.36%	160.20%
Net Cash Per Share	10.41	8.43	6.00	4.77	6.93	8.78
Filing Date Shares Outstanding	62.52	61.38	58.27	51.28	48.41	43.81
Total Common Shares Outstanding	62.45	61.04	57.71	49.34	47.84	43.75
Working Capital	541.48	544.24	334.3	211.9	296.72	275.37
Book Value Per Share	10.34	11.06	5.83	4.37	6.27	6.39
Tangible Book Value	645.44	675.3	336.68	215.61	300.02	279.61
Tangible Book Value Per Share	10.34	11.06	5.83	4.37	6.27	6.39
Machinery	9.13	7.8	6.47	5.91	5.18	4.19
Leasehold Improvements	2.91	2.42	0.96	0.91	0.88	0.75

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q